Vergelijking

Linaclotid vs. Pasireotid

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

851199-59-2

396091-73-9

Molecuulmassa

1526.74 g/mol

1047.21 g/mol

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Linaclotid

Linaclotide activates the guanylate cyclase-C receptor on the luminal surface of the intestinal epithelium. This raises cyclic GMP (cGMP), increases secretion of chloride and bicarbonate into the lumen, raises stool fluid content and accelerates transit; pain signaling is also modulated.

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Linaclotid	Pasireotid
Duitsland	Op recept	Op recept
Verenigde Staten	Op recept	Op recept

Volledige vermeldingen

Linaclotid

Volledige vermelding →

Pasireotid

Volledige vermelding →

Frequently asked questions

What is the difference between Linaclotid and Pasireotid?: Linaclotid is classified as "Onderzoek (overig)", while Pasireotid is classified as "Onderzoek (overig)". Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Linaclotid or Pasireotid?: The highest available evidence level is "Humane RCT" for Linaclotid and "Humane RCT" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Linaclotid and Pasireotid in Germany and the United States?: Duitsland: Linaclotid — Op recept, Pasireotid — Op recept. Verenigde Staten: Linaclotid — Op recept, Pasireotid — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Linaclotid

Pasireotid

Duitsland

Op recept

Verenigde Staten

Op recept

Frequently asked questions

What is the difference between Linaclotid and Pasireotid?

Linaclotid is classified as "Onderzoek (overig)", while Pasireotid is classified as "Onderzoek (overig)". Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Linaclotid or Pasireotid?

The highest available evidence level is "Humane RCT" for Linaclotid and "Humane RCT" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Linaclotid and Pasireotid in Germany and the United States?

Duitsland: Linaclotid — Op recept, Pasireotid — Op recept. Verenigde Staten: Linaclotid — Op recept, Pasireotid — Op recept. These are factual summaries with source and review date on the individual pages.